Vaxart Inc. (VXRT)
Symbol Info
Listed Symbol VXRT
Name Vaxart Inc.
Share Info
Annual Info
Latest Fiscal Dividend Per Share $-
Latest Fiscal Date 2018-12-31
Latest Fiscal Revenue $4,159,000
Latest Fiscal EPS $-2.34
Price Info
21 Day Moving Average $0.6755
21 Day EMA $0.660690
50 Day Moving Average $0.6774
50 Day EMA $0.687590
200 Day EMA $1.379370
200 Day Moving Average 1.286380
52 Week High $7.60
52 Week Low $0.55
52 Week Change $-80.000000
Alpha -0.048252
Beta 0.5950
Standard Deviation 0.174637
R2 0.013760
Periods 60
Share Information
10 Day Average Volume 502,328
20 Day Average Volume 347,165
30 Day Average Volume 306,522
50 Day Average Volume 220,660
Outstanding Shares 15,785,735
Float Shares 13,220,420
Percent Float 83.75%
Short Interest -
Short Percent Float -
Short Interest Ratio -
Short Date
Holders
Institutions 36
Institute Holdings Date 2019-08-31
Institute Bought Previous 3 Months 452,918
Institute Holdings Percent 8.000000
Institute Sold Previous 3 Months 43,989
Insider Holdings Date
Insider Bought Previous 3 Months -
Insider Holdings Percent -
Insider Sold Previous 3 Months -
Insiders Shares Owned 2,565,315
Price Change
7 Day Price Change $-0.091
7 Day Percent Change -13.98%
21 Day Price Change $-0.1448
21 Day Percent Change -20.54%
30 Day Price Change $-0.0967
30 Day Percent Change -14.73%
Month To Date Price Change $-0.1448
Month To Date Percent -20.54%
90 Day Price Change $-0.1856
90 Day Percent Change -24.89%
Quarter To Date $-0.1101
Quarter To Date Percent -16.43%
180 Day Price Change $-1.52
180 Day Percent Change -73.08%
200 Day Price Change $-1.11
200 Day Percent Change -66.47%
Year To Date $-1.32
Year To Date Percent -70.21%
Profile
Description Vaxart Inc is a biopharmaceutical company. It is focused on the discovery and development of direct-acting antivirals to treat infections that affect patients globally. The company has three product candidates which are; vapendavir, an oral treatment for human rhinovirus (HRV) upper respiratory infections in moderate-to-severe asthmatics; BTA585, an oral fusion protein inhibitor for the treatment and prevention of respiratory syncytial virus (RSV) infections, and BTA074, a topical antiviral treatment in for condyloma caused by human papillomavirus.
Details
Issue Type CS
Market Cap $8,840,012
Sec Type EQS
Auditor KPMG LLP
Total Shares Outstanding 15,785,735
CEO Wouter W. Latour
Employees 34
Last Audit UE
Classification
CIK 0000072444
Industry Biotechnology
Sector Healthcare
NAICS Biological Product (except Diagnostic) Manufacturing(325414)
Info
Address 290 Utah Avenue
Suite 200
South San Francisco, CA 94080
Website http://www.aviragen.com
Facisimile +1 650 871-8580
Telephone +1 650 550-3500
Email
Key Ratios
Profitability
EBIT Margin -205.3
EBITDA Margin -154
Pre-Tax Profit Margin -287.1
Profit Margin Cont -
Gross Margin -
Profit Margin TOT -
Income Statements
Revenue $7,540,000
Revenue Per Share $0.4776
Revenue 3 Years $-15.02
Revenue 5 Years $-37.06
Valuation Measures
PE Ratio -
Enterprise Value $-2,142,222
Price To Sales 1.172415
Price To Free Cash -0.6
PE High Last 5 Years -
Price To Book 0.7
Price To Cash Flow 20.1
PE Low Last 5 Years -
Price To Tangible Book -5
Financial Strength
Total Debt To Equity 0.2
Int Coverage -5.9
Current Ratio 2.3
Leverage Ratio 2.7
Quick Ratio 2.2
Long Term Debt To Capital 0.08
Assets
Receivables Turnover 24.0
Invoice Turnover -
Assets Turnover 0.20
Management Effectiveness
Return Assets -43.97
Return On Equity -97.92
Return On Capital -68.74
Dividends
Dividend 3 Years $-
Dividend 5 Years $-
Ex Dividend Date
Dividend Rate $-
Dividend Yield -
Payment Type


Your Recent History
NASDAQ
VXRT
Vaxart
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.